Showing 2361-2370 of 4063 results for "".
- Roche Begins Shipments of First 400,000 COVID-19 Tests to Laboratories Across UShttps://modernod.com/news/roche-begins-shipments-of-first-400000-covid-19-tests-to-laboratories-across-us/2477397/Roche announced that it has begun shipping the first allotment of its cobas SARS-CoV-2 Test for COVID-19 (coronavirus) to a network of hospital and reference laboratories across the U.S. to enable automated, high-volume patient testing. Shipping of the initial 400,000 test kits began
- WHO Declares COVID-19 Outbreak a Pandemic; Eye Care Meetings Cancelledhttps://modernod.com/news/who-declares-covid-19-outbreak-a-pandemic/2477374/The World Health Organization on Wednesday said the COVID-19 outbreak can now “be characterized as a pandemic.” The declaration by Director-General Tedros Adhanom Ghebreyesus was made after he noted that “in the past 2 weeks the number of cases outside China has increased thirteen-fold and the nu
- Biogen, Eli Lilly, Takeda Ask Staff to Work From Home to Limit Coronavirus Spreadhttps://modernod.com/news/biogen-eli-lilly-takeda-ask-staff-to-work-from-home-to-limit-coronavirus-spread/2477367/Eli Lilly and Takeda have asked employees to work from home where possible to reduce the risk of coronavirus transmission in the wake of a number of people who attended a management meeting held by Biogen testing positive for SARS-CoV-2. The meeting was held late last month in Boston. Scot
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- Tom Frinzi to Retire; Warren Foust Appointed President of J&J Vision Surgicalhttps://modernod.com/news/tom-frinzi-to-retire-from-johnson-replaced-by-warren-foust/2477156/Johnson & Johnson Vision announced that Warren Foust will assume the role of Worldwide President, Surgical for Johnson & Johnson Vision, effective December 2. Mr. Foust replaces Tom Frinzi, who will retire at the end of 2019 after a 35-year career in ophthalmology. Mr. Frinzi was
- Eylea Injection Prefilled Syringe Now Availablehttps://modernod.com/news/eylea-injection-prefilled-syringe-now-available/2477154/Regeneron announced that the Eylea (aflibercept) prefilled syringe is now available for doctors to order. The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials. Eylea is the
- New ECP and Parent Survey Shows the Significant Need for Myopia Educationhttps://modernod.com/news/new-ecp-and-parent-survey-shows-the-significant-need-for-myopia-education/2477070/One in four children in the United States is myopic, but according to The Harris Poll survey results released by CooperVision, only 33% of parents know what that term means,2 or how it can affect their children’s future eyesight. This corroborates the finding that 97% of ECPs agree par
- Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Diseasehttps://modernod.com/news/integrated-clinical-trial-analyses-further-substantiate-that-teprotumumab-significantly-improves-debilitating-effects-of-thyroid-eye-disease/2477063/Horizon Therapeutics announced integrated, pooled efficacy data from the phase 2 and phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in inflammation, proptosis (eye bulg
- New Approach to Slowing Nearsightedness in Children Shows Promisehttps://modernod.com/news/new-approach-to-slowing-nearsightedness-in-children-shows-promise/2477006/Combining two different treatment methods to slow the progression of myopia may deliver better results than either can achieve on their own. A new, 2-year study shows that treating children with eye drops and contact lenses was 28 percent to 38 percent more effective in slowing myopia. The resear